- Home
- KROS vs SEPN Comparison
KROS vs SEPN Comparison
Compare KROS & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- SEPN
- Stock Information
- Founded
- KROS 2015
- SEPN 2022
- Country
- KROS United States
- SEPN United States
- Employees
- KROS N/A
- SEPN N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- SEPN
- Sector
- KROS Health Care
- SEPN
- Exchange
- KROS Nasdaq
- SEPN NYSE
- Market Cap
- KROS 565.0M
- SEPN 522.7M
- IPO Year
- KROS 2020
- SEPN 2024
- Fundamental
- Price
- KROS $14.51
- SEPN $13.83
- Analyst Decision
- KROS Buy
- SEPN Strong Buy
- Analyst Count
- KROS 13
- SEPN 5
- Target Price
- KROS $20.63
- SEPN $26.75
- AVG Volume (30 Days)
- KROS 450.7K
- SEPN 261.4K
- Earning Date
- KROS 08-06-2025
- SEPN 08-15-2025
- Dividend Yield
- KROS N/A
- SEPN N/A
- EPS Growth
- KROS N/A
- SEPN N/A
- EPS
- KROS 0.11
- SEPN N/A
- Revenue
- KROS $214,713,000.00
- SEPN $977,000.00
- Revenue This Year
- KROS $5,390.70
- SEPN $3,429.67
- Revenue Next Year
- KROS N/A
- SEPN N/A
- P/E Ratio
- KROS $133.17
- SEPN N/A
- Revenue Growth
- KROS 91657.70
- SEPN 108.76
- 52 Week Low
- KROS $9.12
- SEPN $4.17
- 52 Week High
- KROS $72.37
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- KROS 58.66
- SEPN N/A
- Support Level
- KROS $14.18
- SEPN N/A
- Resistance Level
- KROS $14.85
- SEPN N/A
- Average True Range (ATR)
- KROS 0.55
- SEPN 0.00
- MACD
- KROS 0.04
- SEPN 0.00
- Stochastic Oscillator
- KROS 71.78
- SEPN 0.00
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.